A study published published in JNCCN—Journal of the National Comprehensive Cancer Network analyzes the cost-effectiveness of olaparib, a PARP inhibitor, in the treatment of metastatic pancreatic cancer.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe